thetic seleno-organic compound, has strong antioxidant and Aflatoxin B 1 (AFB 1 ), a potent hepatocarcinogen, enhances anti-inflammatory properties with very low toxicity (12). It ROS formation and causes oxidative DNA damage, which is now under active investigation as a neuroprotective agent may play a role in its carcinogenicity. We have demonin clinical trials (12). Although its antioxidant capabilities strated recently that ebselen, an organic selenium comhave been extensively investigated, relatively little is known pound, protects against the cytotoxicity of AFB 1 through about its anticarcinogenic effect. A previous study showed its antioxidant capability. The present study was designed that ebselen inhibited 12-O-tetradecanoylphorbol-13-acetate to investigate the effect of ebselen on AFB 1 -induced hepato-(TPA)-induced down-regulation in gap-junctional intercellular carcinogenesis in an animal model. Fischer 344 rats were communication (GJIC) (13). Reduction in GJIC has been first treated with either deionized water or ebselen (5 mg/ proposed to be involved in the development of a number of kg, 5 days/week) via gavage for 4 weeks, then given AFB 1 pathogeneses, especially carcinogenesis (14). We recently (0.4 mg/kg, gavage, once a week) or AFB 1 plus ebselen (5 demonstrated that ebselen is potent in protecting against ROSmg/kg, 5 days/week) for another 24 weeks. The results induced cytotoxicity and DNA damage in HepG 2 cells (15). showed that the hepatocarcinogenicity of AFB 1 in rats was Ebselen also protects against the cytotoxicity of AFB 1 via its significantly reduced by ebselen treatment as indicated by strong ability to scavenge intracellular ROS and preventing a decrease in: (i) serum γ-glutamyl transpeptidase activity; oxidative damage (16). The present study was designed to study (ii) expression of mRNAs of liver α-fetoprotein and the the effect of ebselen on AFB 1 -induced liver carcinogenesis in placental form of glutathione S-transferase (GST-P); and Fischer 344 rats. 
Introduction
were purchased from MBI Fermentas (Vilnius, Lithuania). Recombinant RNAsin ribonuclease inhibitor and Blue/Orange 6ϫ loading dye were from Aflatoxin B 1 (AFB 1 ) is a potent hepatocarcinogen in experiPromega (Madison, WI). HotStar Taq DNA polymerase was purchased from mental animals and an etiological factor in human liver cancer Qiagen GmbH (Hilden, Germany). The gene-specific primers for PCR were (1, 2) . It is generally believed that AFB 1 is activated mainly synthesized by Genset Singapore Biotech (Singapore).
by cellular cytochrome P450 (CYP450) to form the reactive
Animals and treatments
intermediate, AFB 1 -8,9-epoxide (AFBO). The subsequent Male Fisher 344 rats (140-180 g body wt) were obtained from the animal covalent binding of this epoxide to DNA to generate AFB 1 -center at the National University of Singapore. All animals received humane DNA adducts is considered to be a critical step in the care, in compliance with the university's and NIH's guidelines. They were housed in plastic cages with a 12 h light-12 h dark cycle at room temperature carcinogenicity of AFB 1 (3,4). AFB 1 also induces formation and allowed free access to tap water and animal feed (Glen Forrest, of reactive oxygen species (ROS) (5), lipid peroxidation (6,7)
Stockfeeders, Glen Forrest, Australia). After a 5 day acclimatization period, 40 rats were randomly assigned into four groups according to their body weight. Figure 1 illustrates the design of the experiment, which lasted for 28 weeks. Abbreviations: AFB 1 , aflatoxin B 1 ; AFB 1 -FAPY, 2,3-dihydro-2-(N 5 -formyl-2,5,6-triamino-4-oxopyrimidin-N 5 -yl-)-3-hydroxy-AFB 1 ; AFBO, AFB 1 -8,9- In the control group (group I) and the group given ebselen only (group II), rats were gavaged with deionized water or with ebselen (5 mg/kg body wt/ epoxide; AFP, α-fetoprotein; ALT, alanine aminotransferase; CYP450, cytochrome P450; DAB, diaminobenzidine; dG, deoxyguanosine; DMSO, day; 5 days/week), respectively, throughout the experiment. In the groups given AFB 1 alone (group III) or together with ebselen (group IV), animals dimethylsulfoxide; dNTPs, deoxynucleotide triphosphates; GGT, γ-glutamyl transpeptidase; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; GST-P, were first given deionized water or ebselen (5 mg/kg body wt/day; 5 days/ week), respectively, via gavage for 4 weeks followed by administration of glutathione S-transferase, placental form; HCC, hepatocellular carcinoma; 8-OHdG, 8-hydroxydeoxyguanosine; ROS, reactive oxygen species; RT-PCR, AFB 1 (0.4 mg/kg body wt, once a week by gavage) (group III) or ebselen plus AFB 1 (group IV) for another 24 weeks. The general condition of each reverse transcription-polymerase chain reaction.
(200 µM each dNTP), PCR primers (100 pmol) and HotStar Taq polymerase (2.0 units per 20 µl) was used to ensure that these were not limiting factors in the PCR analysis. All PCR reactions were carried out in the linear, quantitative phase of the amplification process, which was determined in preliminary experiments. The levels of mRNA expressions of AFP and GST-P transcripts were normalized to that of the constitutively expressed housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (G3PDH), mRNA in the same tissue sample (20) . The sequences of the PCR primers were as follows: AFP upper primer: 5Ј-CAAAGCGGGGTGGAAAGACA-3Ј; AFP lower primer: 5Ј-GCCGAGCTCGATGGTGGGTAGT-3Ј (this paper; based on accession no. X02361); GST-P upper primer: 5Ј-ACGCAGCTTTGA-GTCCACACC-3Ј; GST-P lower primer: 5Ј-GCAGGGCCTTCACATAGTC-ATCC-3Ј (this paper; based on accession no. X02904); G3PDH upper primer: 5Ј-CCCTTCATTGACCTCAACTACATGG-3Ј; G3PDH lower primer: 5Ј-CATGGTGGTGAAGACGCCAG-3Ј (20) .
The PCR products were size fractionated on 1.2% agarose gels, visualized by ethidium bromide staining and photographed. The photographs of the gels were scanned with a GS-700 imaging densitometer (Bio-Rad, Hercules, CA). The densities of the bands produced by the PCR products were quantified using Molecular Analyst software (Bio-Rad). In order to compare mRNA levels between different groups, the transcripts were normalized against the corresponding control G3PDH transcript with matched PCR conditions. The identities of the PCR products were confirmed by sequence analysis.
Immunohistochemical analysis of GST-P foci in rat liver tissue
Histochemical detection of GST-P foci in rat liver is commonly used as a marker for AFB 1 -induced hepatocarcinogenesis (21) . In the present study, Fig. 1 . Schematic representation of ebselen and AFB 1 treatment in Fischer GST-P foci were assayed by an immunohistochemical method using a 344 rats. Group I (control): rats were treated with deionized water via streptavidin-biotin-peroxidase complex (ABC) as described by Hsu et al. gavage; group II (ebselen control), rats were treated with ebselen (5 mg/kg (22) . Briefly, liver slices (3-5 mm thick) were embedded in paraffin and cut body wt/day; 5 days/week) via gavage; group III (AFB 1 treatment only), into 5 µm thick sections. After being deparaffinized with xylene, quenched rats were first gavaged with deionized water for 4 weeks, then treated with with hydrogen peroxide and blocked with normal serum, the liver tissue AFB 1 (0.4 mg/kg body wt, once a week) via gavage for another 24 weeks; sections were incubated with primary antibody (mouse anti-GST-P; Transducand group IV (ebselen plus AFB 1 treatment), rats were first treated with ebselen (5 mg/kg body wt/day, 5 days/week by gavage) for 4 weeks, tion Laboratories, Lexington, KY) and then with secondary antibody (antifollowed by administering AFB 1 (0.4 mg/kg body weight, once a week by mouse Ig-G; Vector Laboratories, Burlingame, CA). The tissue sections were gavage) and ebselen for another 24 weeks.
then incubated with ABC complex (ABC peroxidase staining kit; Vector Laboratories), stained with DAB substrate (DAB substrate kit; Vector Laboratories) and counterstained with hematoxylin. rat was monitored daily and the body weight was recorded weekly throughout Staining of GST-P foci in liver tissue section was analyzed and quantified the experiment. Ebselen and AFB 1 were dissolved in DMSO and diluted with using an image analyzer (KS 300; Carl-Zeiss, Hamberg, Germany). The deionized water to the required concentrations just before gavage. An equal system was able to detect the number of GST-P foci per cm 2 section, the amount of DMSO was given to control animals during the gavage to balance percentage of section area occupied by the foci and the mean density of the concentration of DMSO given to ebselen-and/or AFB 1 -treated rats.
staining of the foci. While the GST-P staining was localized in altered foci in the rat treated with ebselen and AFB 1 together (group IV), much of the liver Blood collection and tissue preparation was stained positive for GST-P in the rat treated with AFB 1 only (group III), Twenty-four hours after the last AFB 1 dose, rats were killed under anesthesia making it inappropriate to count the number of discrete foci. Instead, the with a mixture of fentanyl citrate and fluanisone (Janssen Pharmaceutica, percentage of section area occupied by the foci and the mean density of the Brussels, Belgium) and midazolan (F.Hoffmann-La Roche, Basel, Switzerland).
foci staining were analyzed. Midline laparotomy of each rat was carried out, a blood sample was collected for isolation of serum and the liver was quickly removed, washed and weighed.
Measurement of AFB 1 -DNA adducts in rat liver Liver tissue was homogenized in 0.25 M sucrose, 50 mM Tris buffer (pH 7.4) Early studies have demonstrated that the initial major form of AFB 1 -DNA for DNA extraction. For RNA analysis, liver sections were harvested into adduct is AFB 1 -N 7 -Gua (1,23). However, AFB 1 -N 7 -Gua is not stable and the Trizol solution, frozen in liquid nitrogen and stored at -80°C until analysis. majority of remaining AFB 1 -DNA adducts in rat liver 24 h after AFB 1 Liver tissues were also fixed in buffered 4% paraformaldehyde for paraffin sectreatment is an imidazole ring-opened formamidopyrimidine (AFB 1 -FAPY) tioning.
derivative (1, 24) . In the present study, AFB 1 -FAPY was liberated from hepatic Measurement of serum alanine aminotransferase and γ-glutamyl transpeptid-DNA using acidic conditions and determined using an HPLC method as ase activity previously described (25) . Briefly, DNA was extracted using chloroform Increased serum alanine aminotransferase (ALT) activity is a general index without phenol as described earlier (8). Five hundred micrograms of DNA in reflecting liver cell damage (6), while increased serum γ-glutamyl transpep-10 mM Tris-HCl was hydrolyzed in 0.3 N HCl at 100°C for 2 h and the tidase (GGT) activity is an indicator of the carcinogenicity of AFB 1 (17) .
hydrolysate was applied to a C 18 Sep-Pak cartridge. The cartridge was washed Activities of ALT and GGT in rat serum were measured using an Abbott VP with 0.05 N acetic acid and AFB 1 -DNA adducts were eluted with methanol. Biochemical Analyzer with the appropriate test kits (Abbott Laboratory, The eluent was analyzed by HPLC with a Whatmann Partisphere C 18 column, Chicago, IL). monitored using a Shimadzu fluorescence detector (excitation, 360 nm; Analysis of AFP and GST-P transcripts in rat liver emission, 425 nm). The standard AFB 1 -FAPY was treated in exactly the same manner as the DNA samples; results are expressed as peak heights. AFP and GST-P are widely used as biomarkers of hepatocellular carcinoma (HCC) and have been used to evaluate various carcinogens including AFB 1 -Determination of 8-OHdG formation in rat liver induced hepatocarcinogenesis (18, 19) . In the present study, the expression of Formation of 8-OHdG in rat liver DNA was determined using HPLC linked AFP and GST-P mRNA in rat liver was investigated by reverse transcriptionto an electrochemical detector (ECD) as previously described (8). Briefly, polymerase chain reaction (RT-PCR). Briefly, total RNA was extracted using 200 µg DNA was denatured and then digested by incubation with DNase I, Trizol solution and treated with DNase I (MessageClean kit) to remove nuclease P1 or alkaline phosphatase. The digested DNA was dissolved in contaminating genomic DNA from the RNA samples. Reverse transcription deionized water and 8-OHdG was determined by HPLC, which consisted of reactions were carried out using Superscript RNase H -reverse transcriptase a Waters 600E pump, a Whatman Partisphere C 18 column and a UV detector according to the manufacturer's instructions. AFP-specific fragments were (Hewlett-Packard 1050, λ 254 nm) connected to an ECD (Hewlett-Packard amplified by 38 cycles of PCR, each cycle comprising 30 s at 95°C, 30 s at 1049A) in series for monitoring dG and 8-OHdG, respectively. The results 57.6°C and 30 s at 72°C. GST-P-specific fragments were amplified by 27 cycles of 30 s at 95°C, 30 s at 58°C and 30 s at 72°C. An excess of dNTPs are expressed as 8-OHdG/10 5 dG. 
Results

General effects of ebselen and AFB 1 treatment
The general condition of the rats was monitored daily throughout the experiment; no obvious changes were detected in any rats. The body weight of rats in all four groups increased significantly during the experimental period. Neither ebselen nor AFB 1 had any obvious effect on rat body weight gain. wt) (group II) for 28 weeks was not significantly different from that in control animals (group I) ( Table I) . GGT activity PCR; Figure 3 ) and the protein level (by immunohistochemical was not detected in control or ebselen-treated rats (Table I). analysis; Figure 4 ). PCR amplification of fragments specific Serum ALT and GGT activity in rats treated with AFB 1 (0.4 to GST-P yielded a product of 409 bp (Figure 3a) . No significant mg/kg body wt) (group III) for 24 weeks was significantly difference in GST-P mRNA expression was observed in higher than that of control animals (group I) ( Table I) . Serum control (group I) and ebselen-treated (group II) animal livers ALT and GGT activities in rats treated with ebselen and AFB 1 ( Figure 3b ). The expression of GST-P mRNA in AFB 1 -treated together (group IV), however, were significantly lower than rat livers (group III), however, was 50.5% higher than that in those in animals treated with AFB 1 alone (group III) (Table control animals (group I) (Figure 3 ). Treatment with ebselen I), suggesting that ebselen treatment could reduce AFB 1 -and AFB 1 together (group IV), on the other hand, resulted in induced rat liver damage and carcinogenesis. a marked reduction (44.7%) in the amount of AFB 1 
-induced Effect of ebselen on AFB 1 -induced expression of AFP mRNA
GST-P transcript. Expression of the AFP transcript in rat liver was investigated AFB 1 -induced formation of GST-P foci in rat liver and the by RT-PCR; the results are shown in Figure 2 . PCR amplificainhibitory effect of ebselen are shown in Figure 4 and Table tion of fragments specific for AFP yielded a fragment of II. No GST-P foci were observed in control (group I) or 588 bp (Figure 2a) . The values from densitometric analysis, ebselen-treated (group II) rats (Figure 4a and b) . In rats treated after normalization against the corresponding G3PDH tranwith AFB 1 only (group III), much of the liver stained positive script (209 bp), were expressed as the AFP:G3PDH ratio for GST-P (Figure 4c ), whereas in rats treated with ebselen ( Figure 2b ). It was found that while both control (group I) and and AFB 1 together (group IV), GST-P staining was much less ebselen-treated (group II) rat livers expressed AFP transcripts at extensive and localized at the altered foci (Figure 4d ). Using low levels, treatment with AFB 1 (group III) led to a 93.2% a computer-based image-analysis system, AFB 1 -induced GSTincrease in AFP mRNA level (Figure 2 ). AFP mRNA expres-P foci were further quantified by analysis of (i) the percentage sion in rats treated with ebselen and AFB 1 together (group of section area occupied by the foci and (ii) the mean density IV) was 47.1% lower than that in rats treated with AFB 1 alone of staining of the foci staining; the results are presented in (group III) (Figure 2 ). These results indicate that treatment Table II . Compared with rats treated with AFB 1 only (group with ebselen significantly reduced the level of expression of III), the percentage of section area occupied by the foci and AFP transcript in AFB 1 -treated rat livers.
the mean density of staining were significantly reduced, by Effect of ebselen on AFB 1 -induced expression of GST-P mRNA 51.6% (from 13% Ϯ 3.5% to 6% Ϯ 1.9%) and 24% (from in rat liver and formation of GST-P foci 64 Ϯ 19.2 to 49 Ϯ 8.2), respectively, in the rats treated with ebselen and AFB 1 together (group IV) ( Table II) . The effect of ebselen treatment on AFB 1 -induced GST-P in rat liver was investigated at both the mRNA level (by RTSerum GGT activity measurement (Table I) , RT-PCR ana-
Discussion
We have shown previously that ebselen can protect against AFB 1 -induced cytotoxicity in primary rat hepatocytes through its antioxidant property (16) . In the present study, we further demonstrate that ebselen can also inhibit AFB 1 -induced liver preneoplastic alterations in Fischer 344 rats, as shown by the significant reduction in (i) serum GGT activity (by 63.4%) ( Table I) ; (ii) expression of AFP mRNA in liver (by 47.1%) ( Figure 2) ; (iii) expression GST-P mRNA in liver (by 44.7%) ( Figure 3) ; and (iv) the area and mean density of staining of GST-P foci in the liver (by 51.6% and 24.0%, respectively) ( Figure 4 and Table II) . It is well known that AFB 1 is an indirectly acting carcinogen and that it is activated primarily by CYP450. The binding of its reactive metabolite, AFBO, to DNA to form AFB 1 -DNA adducts accounts for its carcinogenicity, whereas conjugation of AFBO with glutathione results in detoxification of this potent carcinogen (3,4). As AFB 1 poses a great health risk in many parts of the world, a great deal of effort has been made to investigate the protective effect of various chemical agents against AFB 1 carcinogenicity (26). Many chemopreventive agents have been demonstrated to reduce AFB 1 -DNA adduct formation via inhibition on CYP450-mediated AFB 1 activation and/or enhancing its detoxification through the conjugation with GSH catalyzed by cytosolic α-class GSTs (26, 27) . For instance, high concentrations of phenolic antioxidants [butylated hydroxyanisole (BHA) and butylated hydroxytolu- inhibition of ebselen on AFB 1 -induced hepatic preneoplastic alterations, we first examined the effect of ebselen treatment on the formation of AFB 1 -DNA adducts in rat liver. Ebselen lysis of hepatic AFP and GST-P transcripts (Figures 2 and 3) treatment significantly inhibited hepatic formation of AFB 1 -and liver immunohistochemical detection of GST-P foci ( Figure  DNA adducts (Table III) . It has been shown previously that 4 and Table II ) thus suggest that ebselen can inhibit the ebselen inhibits mouse liver microsomal NADPH-dependent carcinogenicity of AFB 1 .
CYP450 reductase and converts rat liver microsomal CYP450 Effect of ebselen on the level of AFB 1 -DNA adducts in rat liver to CYP420 in cell-free systems via interaction with sulfhydryl To explore the mechanisms responsible for the inhibitory effect groups of proteins (30, 31) . In vivo, however, ebselen is of ebselen on AFB 1 carcinogenicity, the effect of ebselen on unlikely to inhibit microsomal CYP450, because most of the AFB 1 -DNA adduct (AFB 1 -FAPY) formation was investigated.
administered ebselen would combine with serum proteins No AFB 1 -FAPY was detected in the control (group I) or (albumin) and intracellular thiols (glutiathione) before reaching ebselen-treated (group II) animals (Table III) . The level of CYP450 located in the endoplasmic reticulum (30, 32) . Indeed, AFB 1 -FAPY in rats treated with ebselen and AFB 1 together in mice fed a diet containing ebselen (200 mg/kg) for 1 week, (group IV) was significantly lower than that of rats treated there was no effect on liver microsomal NADPH-dependent with AFB 1 only (group III) (Table III), indicating that ebselen CYP450 reductase activity, ethoxycoumarine-O-deethylation inhibits AFB 1 -DNA adduct formation in rat liver.
rate or the amounts of CYP450 and cytochrome b 5 (30) . Also, Effect of ebselen on AFB 1 -induced 8-OHdG formation in a much higher oral dose of ebselen (500 mg/kg body wt) does rat liver not inhibit liver metabolism of the xenobiotics in mice (33). Although changes in AFB 1 metabolism by CYP450 were not The effect of ebselen on AFB 1 -induced 8-OHdG formation in studied in the present study, it is believed that oral administrarat liver was investigated; the results are shown in Figure 5 . tion of ebselen (5 mg/kg body wt) is not likely to affect the No significant difference in 8-OHdG concentrations between liver microsomal metabolism of AFB 1 significantly. Therefore, the control (group I) and ebselen-treated (group II) rats it seems that the inhibition by ebselen of hepatic AFB 1 -DNA was observed. However, a significant increase in 8-OHdG adduct formation may not be due to modulation by ebselen of concentration was noted in rats treated with AFB 1 only (group AFB 1 activation by CYP450. Although no direct evidence is III). The concentration of 8-OHdG in rats treated with AFB 1 available at present, it is believed that ebselen treatment might and ebselen together (group IV) was significantly lower than affect the AFB 1 detoxification pathway catalyzed by GSTs, that in animals treated with AFB 1 only (Figure 5 ), suggesting thus reducing the level of hepatic AFB 1 -DNA adducts. Further that ebselen can protect against AFB 1 -induced oxidative DNA damage.
study is needed to clarify the possible mechanisms responsible for the inhibition of ebselen on hepatic AFB 1 -DNA adduct *Significantly different from control (group I) (P Ͻ 0.05, one-way ANOVA formation.
with Scheffe's test); # significantly different from treatment with AFB 1 alone (group III) (P Ͻ 0.05; one-way ANOVA with Scheffe's test).
There are some discrepancies in studies of the relationship between the level of hepatic AFB 1 -DNA adducts and ability to protect against AFB 1 carcinogenicity. For example, a recent efficiently as other carotenoids that dramatically inhibited the formation of hepatic AFB 1 -DNA adducts (34) . In addition, as study indicated that dietary administration of β-carotene had no obvious effect on the formation of AFB 1 -DNA adducts in mentioned above, the protection by high concentrations of BHA and BHT against AFB 1 carcinogenicity results from the rat liver, but reduced AFB 1 -induced liver GST-P foci as metabolism of AFB 1 . Therefore, the observed protective effect ebselen treatment significantly reduced the levels of both *Significantly different from treatment with AFB 1 alone (group III) AFB 1 -DNA adduct (Table III) liver. It is, therefore, believed that ebselen prevents AFB 1 -induced preneoplastic changes by inhibiting the formation of AFB 1 -DNA adducts and the ROS-scavenging ability of inhibition of AFB 1 -DNA adduct formation through their strong induction of GST activity. Williams and Iatropoulos (35), ebselen. On the other hand, ebselen could act by inhibiting AFB 1 -DNA adduct formation when AFB 1 concentrations are however, showed that low concentrations of BHA and BHT, which are not able to induce GST activity, still significantly low, conditions where AFB 1 -DNA adduct formation is known to play a more important role in its carcinogenicity. inhibit hepatocarcinogenesis of AFB 1 in rats. This evidence thus suggests that there may be other mechanisms responsible In summary, the overall results of the present study suggest that ebselen can inhibit the preneoplastic changes caused by for AFB 1 carcinogenicity besides formation of AFB 1 -DNA adducts. It will be of interest to explore further other mechan-AFB 1 . Considering the importance of oxidative DNA damage in carcinogenesis, it is believed that, in addition to the inhibition isms that might be involved in the protective effect of ebselen against AFB 1 carcinogenicity.
of AFB 1 -DNA adduct formation, the protective effect of ebselen against AFB 1 -induced oxidative DNA damage may The role of carcinogen-induced ROS formation and oxidative DNA damage in carcinogenesis has attracted much attention.
also contribute, at least in part, to its anticarcinogenic property. It is now widely believed that oxidative DNA damage is implicated in the development of cancer (10,11,36). There is
